Ten Blind Patients Receive Optogenetic Therapy in New Clinical Trial
Seven out of ten patients blinded by retinitis pigmentosa recovered partial light sensitivity after receiving an experimental optogenetic treatment, according to a clinical trial published on October 7, 2026, in the New England Journal of Medicine. The intervention bypassed damaged photoreceptor cells by injecting algae-derived light-sensitive proteins directly into the retina.
Retinitis pigmentosa destroys the light-sensing cells in the retina. Instead of repairing those cells, researchers targeted retinal ganglion cells, which normally relay visual signals to the brain. Scientists injected gene instructions for the light-sensitive protein ChrimsonR into the patients’ eyes.
Special Goggles Translate Light Into Neural Signals
Natural ambient light cannot activate the modified protein on its own. Patients wore custom amber-tinted goggles equipped with a built-in camera that detects brightness changes and projects amber light pulses onto the retina, as New England Journal of Medicine details. Six of the ten patients experienced a light sensitivity increase ranging from 2 to 62.3 times.
Out of eight patients who completed behavioral tests, four were able to find a doorway or follow a line on the ground while wearing the goggles. Some participants could also reach out and grab a notebook placed on a table.
Limitations and Expert Reactions to the Results
None of the participants gained the ability to read text or recognize faces.
Frequently Asked Questions About the Retinal Gene Therapy Trial
What specific disease did the trial participants have?
The ten patients suffered from advanced retinitis pigmentosa, an inherited condition that progressively kills the light-sensitive photoreceptor cells in the retina.
What source organism provided the light-sensitive protein?
The gene instructions injected into the patients’ eyes produce ChrimsonR, a light-sensitive protein derived from green algae.
Did any patients experience adverse safety events?
One participant experienced a temporary central retinal artery occlusion that resolved within minutes following the injection, while the overall safety profile across the ten patients remained favorable.
Worth a look